Details

Autor(en) / Beteiligte

• Ference, Brian A
• Robinson, Jennifer G
• Brook, Robert D
• Catapano, Alberico L
• Chapman, M. John
• Neff, David R
• Voros, Szilard
• Giugliano, Robert P
• Davey Smith, George
• Fazio, Sergio
• Sabatine, Marc S

Titel

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes

Ist Teil von

• The New England journal of medicine, 2016-12, Vol.375 (22), p.2144-2153

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Statins are known to lower levels of LDL cholesterol, protect against cardiovascular disease, and slightly increase the risk of type 2 diabetes. This analysis of genetic variants in 112,772 participants from 14 studies suggests that PCSK9 inhibitors may do the same. Monoclonal antibodies and other therapies that inhibit proprotein convertase subtilisin–kexin type 9 (PCSK9) have been shown to reduce low-density lipoprotein (LDL) cholesterol levels by approximately 50 to 60% in several randomized trials. 1 – 8 Whether lowering LDL cholesterol levels by inhibiting PCSK9 will reduce the risk of cardiovascular events and, like statins, also increase the risk of new-onset diabetes is unknown. 9 Exploratory and post hoc analyses of randomized trials have suggested that lowering LDL cholesterol levels by approximately 70 mg per deciliter (1.81 mmol per liter) with a PCSK9 inhibitor may reduce the risk of major cardiovascular events by up to . . .